FRE.DE | Ticker Profile - Titan Protect

FRE.DE

Fresenius SE

Health Care · Health Care Facilities · XETRA

$36.98

Data: 2026-05-09

✓ ETHICAL PASS

Unknown MOAT

HIGH

Data Confidence: 100.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$23.1B

Total market value of the company

Trailing P/E

15.28

Reasonably valued

Forward P/E

10.49

Based on estimated future earnings — lower means cheaper

Rev Growth

+2.0%

Year-over-year revenue change

Profit Margin

0.0%

How much profit the company keeps from each dollar of revenue

ROE

7.8%

Return on equity — how efficiently it uses shareholder money

Analyst Target

N/A

Recommendation

N/A

Consensus view from ? analysts covering this stock

About Fresenius SE

Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients in North America, Europe, the Asia-Pacific, Latin America, and Africa.

Country: Germany Industry: Medical Care Facilities

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

28.8% PASS

Debt must be below 33% of total assets

Cash Ratio

3.2% PASS

Interest-bearing cash below 33% of assets

Receivables

8.6% PASS

Receivables below 49% of assets

Revenue Purity

1.4% PASS

Non-compliant revenue below 5% — any excess requires purification

Valuation

Fair Value Est.

$12.43

What our model estimates this business is worth per share

Margin of Safety

-197.5%

Trading above fair value — no margin of safety

Rating

OPPORTUNITY

Overall assessment combining ethics, valuation, and quality

Percentile

92.7th

Ranks in the top 7% of our 13,571 screened universe

Ethical Score

82.2

Valuation Score

65.5

Quality Score

33.0

Combined

N/A

Trading at $41, 230% above fair value of $12. Passes all ethical screens. Ranks better than 89% of screened stocks.

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

DISTRIBUTION

Smart money appears to be selling into strength — caution

Sharpe Ratio

0.806

Good returns relative to risk taken

Kelly Fraction

-0.0317

No positive edge detected — the data suggests staying out

Calmar Ratio

0.628

Acceptable balance between returns and drawdown risk

Annual Return

16.6%

Historical annualised return based on price data

Max Drawdown

-26.5%

Largest peak-to-trough decline — the worst it has been

HMM State

SIDEWAYS

Price consolidating — no clear directional bias

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

N/A

52W High

$N/A

52W Low

$N/A

Avg Volume

N/A

Average daily shares traded — higher means easier to buy and sell

Short Ratio

N/A

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

2.6%

Annual dividend as a percentage of the share price

EPS (TTM)

$2.68

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

58.17

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

N/A

Revenue left after cost of goods — higher means pricing power

Operating Margin

10.2%

Profit from core operations before interest and tax

Free Cash Flow

N/A

Negative — the business is spending more than it generates

Revenue (TTM)

N/A

Total revenue over the last 12 months

Net Income

N/A

Loss-making — spending exceeds revenue after all costs

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-09

Before you go